Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NYMOX PHARMACEUTICAL CORPORATION

(NYMX)
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société NYMOX PHARMACEUTICAL CORPORATION
06/11NYMOX PHARMACEUTICAL : Amendment to Annual Report by Foreign Issuer (SEC Filing ..
PU
05/07NYMOX PHARMACEUTICAL : Announces $8,000,000 private placement
PU
05/06Nymox Announces Date for Fexapotide Filing
GL
04/28NYMOX PHARMACEUTICAL : Announces $8,000,000 Private Placement
AQ
03/29Nymox Provides New Update on Regulatory Activities
GL
2020Nymox Provides Update on Regulatory Filing Activities
GL
2020Nymox Announces $9 Million Registered Direct Offering
GL
2020NYMOX Provides Current Update on Key Company Developments
GL
2020Nymox Announces Updates in Regulatory Submissions For Fexapotide Treatment Fo..
GL
2020Nymox Announces Important New Patent Developments
GL
2020Nymox Announces New Peer Review Publication of Prostate Cancer Fexapotide Cli..
GL
2020Nymox Provides Update on Current Corporate Activities and Milestones
GL
2020Nymox Announces New Peer Review Article on Fexapotide Pharmaco-Ablation Exper..
GL
2019Nymox Reports on Newly Issued Patents and Corporate Developments
GL
2019Nymox End of Q2 New Investor Presentation on Website
GL
2019Nymox Reports Pre-NDA CMC Meeting with the FDA
GL
2019NYMOX TELECONFERENCE MONDAY, MARCH 2 : 00 a.m. EDT
GL
2019Nymox Announces Appointment of Mark Staples PhD as Vice President of Chemistr..
GL
2019Nymox Announces Appointment of Russell Thomson Ph.D. as Director of Quality a..
GL
2019New Peer Review Article Entitled “Efficacy and safety of fexapotide tri..
GL
20182018 : A Year of Achievements for NYMOX
GL
2018CORPORATE UPDATE TO SHAREHOLDERS :  Preparatory Work For Regulatory Filings On T..
GL
2018Nymox Reports Safety Benefits of Fexapotide Treatments for Prostate Cancer an..
GL
2018NYMOX Announces Expanded Marketing Plans
GL
2018NYMOX Successfully Achieves Manufacturing Scale-Up
GL
2018Fexapotide Triflutate Pivotal Phase 3 Study Results Presented and Discussed a..
GL
2018Nymox's Fexapotide Featured in Broadcast of Grand Rounds in Urology
GL
2018Nymox Announces Fexapotide Drug Symposium at AUA Annual Meeting San Francisco..
GL
2018NYMOX PHARMACEUTICAL : Announces $16.25 Million Equity Financing With Qualified ..
PU
2018Nymox Announces $16.25 Million Equity Financing With Qualified Long-Term Inve..
GL
2018New Online Commentary in UroToday on Fexapotide BPH Clinical Trial Results Pu..
GL
2018Symposium and Panel Discussion on Nymox's Fexapotide To Be Held at American U..
GL
2018Nymox Announces US NDA for Fexapotide for BPH
GL
2018Fexapotide BPH Phase 3 Clinical Trial Results Published in World Journal of U..
GL
2018Nymox Reports 5-Year Results From Prospective Randomized Controlled Prostate ..
GL
2017Nymox Fexapotide Symposium and Panel Discussion at American Urological Associ..
GL
2017Nymox Fexapotide Symposium and Panel Discussion at American Urological Associ..
GL
2017Symposium and Panel Discussion on Nymox's Fexapotide To Be Held at American U..
GL
2017Nymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexap..
GL
2017Nymox Announces Two Data Presentations for Company's BPH Drug at New York Ame..
GL
2017Nymox Reports on Symposium, Panel Discussion with Abstract on Fexapotide at A..
GL
2017Nymox Reports on Symposium and Panel Discussion on Fexapotide at American Uro..
GL
2017Nymox Announces October 12 Symposium for Company's BPH Drug at American Urolo..
GL
2017NYMOX APPLICATION VALIDATED : Nymox Announces Validation by the European Member ..
PU
2017NYMOX PHARMACEUTICAL : AUA Meeting in Florida September 16 Postponed Due to Hurr..
PU
2017Nymox Application Validated
GL
2017Nymox Announces New Symposium for Company's BPH Drug at American Urological A..
GL
2017AUA Meeting in Florida September 16 Postponed Due to Hurricane
GL
2017NYMOX PHARMACEUTICAL : Announces Symposium for Company's BPH Drug at American Ur..
PU
2017Nymox Announces Private Placements of $3 Million
GL
2017Nymox Announces Symposium for Company's BPH Drug at American Urological Assoc..
GL
2017Sexual Function Improves in First-Line Patients Given Fexapotide Treatment in..
GL
2017NYMOX FILES FOR APPROVAL OF FIRST IN : Teleconference at 4:30 EDT
PU
2017NYMOX FILES FOR APPROVAL OF FIRST IN : Company To Hold Teleconference Wednesday ..
PU
2017NYMOX PHARMACEUTICAL : Files For Marketing Approval For Fexapotide Triflutate in..
PU
2017NYMOX FILES FOR APPROVAL OF FIRST IN : Teleconference at 4:30 EDT
GL
2017NYMOX FILES FOR APPROVAL OF FIRST IN : Company To Hold Teleconference Wednesday ..
GL
2017NYMOX Files For Marketing Approval For Fexapotide Triflutate in Europe
GL
2017NYMOX PHARMACEUTICAL : Provides Update on Fexapotide Development
PU
2017Nymox Provides Update on Fexapotide Development
GL
2016Nymox Reports Additional Positive Results From Completed Fexapotide BPH Phase..
GL
2016NYMOX REPORTS SUCCESSFUL NEW PHASE 3 : Lasting Symptomatic Improvement Up To 6 Y..
GL
2016NYMOX PHARMACEUTICAL : New Phase 3 Long-Term U.S. Results For Prostate Enlargeme..
PU
2016NYMOX REPORTS SUCCESSFUL NEW LONG-TE : Major Reduction in Incidence of Surgery
PU
2016Nymox's New Phase 3 Long-Term U.S. Results For Prostate Enlargement Drug Fexa..
GL
2016NYMOX REPORTS SUCCESSFUL NEW LONG-TE : Major Reduction in Incidence of Surgery
GL
2016NYMOX PHARMACEUTICAL : Announces Prostate Drug Progress
PU
2016Nymox Announces Private Placements of $2.24 Million
GL
2016Nymox Announces Prostate Drug Progress
GL
2016IMPORTANT INVESTOR NOTICE : Lundin Law PC Announces an Investigation of Nymox Ph..
BU
2016Rosen Law Firm Announces Investigation of Securities Claims Against Nymox Pha..
BU
2016Nymox Reports Long-Term Prostate Cancer Results in 7 Year Prospective Study o..
GL
2016NYMOX PHARMACEUTICAL : Announces Prostate Cancer Clinical Trial Results From Com..
PU
2016NYMOX PHARMACEUTICAL : Announces Additional $2.1 Million Equity Financing
PU
2016Nymox Announces Prostate Cancer Clinical Trial Results From Completed 18 Mont..
GL
1  2Next